TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03887754
Drug: Non specific Multivitamin
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: control group received non specific multivitamins as placebo for 8 months.
Study: NCT01318330
Drug: Homeo-GH
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone Marraw derived Clonal Mesenchymal Stem Cell (cMSC)
Study: NCT01440179
Drug: SAR3419
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: concentrate solution for infusion Route of administration: intravenous
Study: NCT00415831
Drug: ELC200 (carbidopa+levodopa+entacapone)
Normalized name: carbidopa / entacapone / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03123718
Drug: Intrathecal methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal administration of 2nd, 3rd, and 4th doses of methotrexate 15 mg and hydrocortisone 50mg on day 2 or 3 of 2nd, 3rd, and 4th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.
Study: NCT03123718
Drug: High-dose intravenous methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 1st and 2nd doses of methotrexate 3g/m2 on day 15 of 2nd and 6th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.~\* Dose of intravenous methotrexate will be reduced to 2g/m2 for patients aged \>70 years.
Study: NCT00919737
Drug: NPC-08
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polifeprosan 20 with Carmustine 3.85%
Study: NCT00746421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg, 300mg or 400mg
Study: NCT01845038
Drug: OTX-TPa ~4µg/day over 2 mos. with natural tears drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTX-TPa is a hydrogel punctum plug eluting travoprost in a sustained release of \~4µg/day over 2 months. Subjects in this arm will also receive natural tears drops.
Study: NCT01845038
Drug: OTX-TPb ~3µg/day over 3 months with natural tears drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTX-TPb is a hydrogel punctum plug eluting travoprost in a sustained release of \~3µg/day over 3 months. Subjects in this arm will also receive natural tears drops.
Study: NCT00913627
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00913627
Drug: naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00913627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01582308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: one placebo for sitagliptin tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
Study: NCT00726687
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine, dose escalation, 875 mg/m2- 1250 mg/m2, taken twice daily for 14 days per 21 day cycle
Study: NCT01229150
Drug: AZD6244
Approvals — FDA: no, EMA: no, PMDA: no
Description: For KRAS mutant patients randomized to the single agent arm, AZD6244 75 mg bid (twice a day).
Study: NCT01032213
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group S received the same volume of isotonic saline as same method.
Study: NCT01322321
Drug: ACZ885
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01322321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02070783
Drug: ARA290
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02070783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04068792
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in each Age Group (1,2,3) will receive matching placebo (volume placebo to match the calculated volume of the JNJ-53718678 dose) orally twice daily for 7 days.
Study: NCT04068792
Drug: JNJ-53718678 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-53718678 will be administered to Age Group 2 twice daily for 7 days.
Study: NCT04068792
Drug: JNJ-53718678 4.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-53718678 will be administered to Age Group 3 twice daily for 7 days.
Study: NCT00725322
Drug: Placebo - Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Saline injection given at site of scar neuroma
Study: NCT01318369
Drug: Namisol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose delta-9-tetrahydrocannabinol
Study: NCT03517319
Drug: Normal Saline 0.9% 1.2 ml
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00730691
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching capsules
Study: NCT00396175
Drug: Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01081028
Drug: Second-line Multiple Myeloma treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed by the treating physician
Study: NCT02669251
Drug: MPH966
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1b Cycle= 14 days: Each dose level will increase by 60mg PO BID, up to a maximum of 240mg PO BID~Phase 2 Cycle=28 days: MTD PO BID
Study: NCT02161679
Drug: IMMU-132 infusion is administered to participants in one arm for the study
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02043522
Drug: Radioisotope
Normalized name: Radioisotope
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of 10 mCi (370 mBq:± 10%, calibrated to time of injection) of 123I-mIBG (AdreView) administered as a single intravenous bolus over 1 or 2 minutes, followed by a saline flush.
Study: NCT03638297
Drug: PD-1 antibody + cox inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAT1306 100mg /pembrolizumab 200mg on day 1 + aspirin 200mg oral (celebrex 400mg oral when there is contraindication to aspirin) on day 1-21 every three weeks~Contraindication to aspirin :~Allergic or intolerance to aspirin; With peptic ulcers; With hemophilia or other bleeding tendencies; Have the gentic disease glucose-6 phosphate dehydrogenase deficiency.
Study: NCT01570361
Drug: Drug Treatment
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (either rate or rhythm control): Class I or class III, or AV nodal blocking agents such as beta blockers and calcium channel blockers in accordance with current atrial fibrillation management guidelines.
Study: NCT04129554
Drug: Placebo for JNJ-56136379
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for JNJ-56136379 tablets will be administered orally up to 48 weeks.
Study: NCT01239004
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 tablets daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
Study: NCT02101853
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02101853
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02101853
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT, IV, and PO
Study: NCT02101853
Drug: Therapeutic Hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IT
Study: NCT00379860
Drug: LXR-623
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02275468
Drug: Fu-zheng-qu-zhuo (FZQZ) oral liquid
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: FZQZ oral liquid is a herbal medicine, composed of astragalus, angelica root, rhubarb, etc, with the effect of reinforcing Qi and activating blood, dissolving dampness and downbearing turbid.
Study: NCT01871961
Drug: Methotrexate (Metoject® prefilled pen)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00874120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken twice daily (12 hours apart) for 7 days.
Study: NCT02153645
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00477165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical to citalopram 20mg capsules; 1 capsule/day for 4 weeks, then 2 capsules/day for 4 weeks
Study: NCT02879305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
Study: NCT02879305
Drug: Iron therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.
Study: NCT00039130
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/sq m/day IV infusion over 5-15 min days 1-5, courses I, III, V, VII
Study: NCT00039130
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/sq m/day IV infusion Days 4 \& 5 courses III,V, VII
Study: NCT00039130
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25mg/sq m IV infusion over 15 min then 10 mg IV q 6 hrs until serum MTX \<10nM, courses II-VII
Study: NCT00039130
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.5 g/sq m IV infusion Day 1 courses II-VII
Study: NCT00908713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chloride 0.9% 10 mL every 12 h for 5 days
Study: NCT01435200
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron 200 mg add in 0.9% Normal saline 100 ml infused within 15 minutes after every cycles of chemotherapy
Study: NCT03471130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, 7 days
Study: NCT02983344
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl
Study: NCT02854631
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg (4 x 10 mg tablets) administered orally once daily
Study: NCT02854631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selonsertib placebo tablet administered orally once daily
Study: NCT04662125
Drug: caffeine, paracetamol tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral fluid intake, recumbent positioning, combination of paracetamol and caffeine tablet three times per day for three days (2 tablets of Panadol-Extra tablet, film coated, GlaxoSmithKline Consumer Healthcare Holdings (US) LLC were given every 8hours) and stool softener and to maintain blinding a tablet of vitamins was given twice per day for three days.
Study: NCT04662125
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients who received conservative treatment as control group together with oral tablet prednisolone 20 mg once daily plus one tablet of vitamins to maintain blinding for three days. .
Study: NCT06074367
Drug: Vitamin C 500 MG Oral Capsule(High dose 2g daily)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sixty CABG patients commenced on maximum tolerated dose of b-blocker, statins \& vitamin C 500 mg (2 g-daily in 4 divided doses) started one day before operation till the end of hospital stay or development of post operative atrial fibrillation
Study: NCT06074367
Drug: placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sixty CABG Patients commenced on maximum tolerated dose of b-blocker, statins and placebo capsules containing starch mimic vitamin C capsules was taken every 6 hrs. The placebo capsules were prepared in the same shape and size as the original ones manufactured by the same pharmaceutical company. the intervention started one day before operation till the end of hospital stay or development of post operative atrial fibrillation.
Study: NCT01421004
Drug: TKI258
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04774328
Drug: CA-008 (vocacapsaicin)
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of CA-008 (vocacapsaicin) versus placebo
Study: NCT04774328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of CA-008 (vocacapsaicin) versus placebo
Study: NCT02872194
Drug: BAY987516, Y55-170
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 uL in one eye
Study: NCT02872194
Drug: BAY987516, X72-151
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 uL in one eye
Study: NCT02872194
Drug: BAY987516, Y49-034
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 uL in one eye
Study: NCT02872194
Drug: Standard shampoo mixture (control)
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 uL in one eye
Study: NCT02129400
Drug: Aer medicinalis Linde 100%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02790203
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSAIDS
Study: NCT02790203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01939652
Drug: Drag: Crystalloids and Colloids
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01375556
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02091492
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo teriparatide sc (subcutaneous injection) each day for 12 weeks
Study: NCT02176499
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01206660
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered to affected area twice a day for 28 days
Study: NCT02708160
Drug: 1.1% Fluoride toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
Study: NCT02708160
Drug: 0.243% Fluoride toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
Study: NCT00297375
Drug: tramadol HCl/acetaminophen
Normalized name: tramadol HCl/acetaminophen 37.5 mg-325 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03100019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04055012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tabs
Study: NCT00630396
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose level 1 = 3mg/kg intravenous (IV) initial dose, followed by 1.5mg/kg every 12 hours times 5 more doses.~Dose level 2 = 4.5mg/kg intravenous (IV) initial dose, followed by 2.25mg/kg every 12 hours times 5 more doses.~Dose level 3 = 6 mg/kg intravenous (IV) initial dose, followed by 3 mg/kg every 12 hours times 5 more doses.~Dose level 4 = 10 mg/kg intravenous (IV) initial dose, followed by 5 mg/kg every 12 hours times 5 more doses
Study: NCT01991210
Drug: DNIB0600A
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNIB0600A will be administered at a dose of 2.4 mg/kg IV every 3 weeks.
Study: NCT01991210
Drug: PLD
Normalized name: PLD1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD will be administered at a dose of 40 mg/m\^2 IV every 4 weeks.
Study: NCT04497688
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received a single dose of PEG-rhG-CSF per cycle. The chemotherapy regimen must meet the interval between two chemotherapy sessions at least 12 days.
Study: NCT01432080
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months
Study: NCT02198274
Drug: BIBH 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/week
Study: NCT01277094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily doses for 12 weeks
Study: NCT01277094
Drug: RO5093151
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily doses for 12 weeks
Study: NCT03754244
Drug: TQB3456
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observe the safety and pk when the subjects take TQB3456 p.o. qd
Study: NCT00571935
Drug: soluble human insulin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02092935
Drug: SMT19969
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00190593
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02323698
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will ingest capsules containing caffeine (up to 6mg/kg). Experiments will begin 30min after consumption to approximately coincide with peak plasma concentrations.Throughout the 30min wait time and experimentation, blood pressure and heart rate will be monitored.
Study: NCT04325581
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline SC daily
Study: NCT00507117
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT00989053
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill per day for 8 weeks
Study: NCT03185208
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: See placebo arm
Study: NCT03669250
Drug: CVN058
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVN058 will be given at two doses, a low does and a high dose
Study: NCT00297830
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug is administered through 5 mg intravenous infusion over 20 minutes
Study: NCT02047890
Drug: BAY1000394 (2.5mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY1000934 2.5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 1)
Study: NCT03341013
Drug: MEDI0382 Formulation 2
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequence 1 Period 1 and Sequence 2 Period 2.
Study: NCT02047890
Drug: BAY1000394 (5mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY1000934 5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 2)
Study: NCT03487276
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01823523
Drug: Cefazolin, Cephalexin, Clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00808366
Drug: Keratolytic/Antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intial treatment with RV4104A ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
Study: NCT00808366
Drug: Keratolytic/Antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with bifonazole-urea ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
Study: NCT03018821
Drug: Standard - Ge Xia Zhu Yu Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ge Xia Zhu Yu Decoction is one Chinese Medicine Formula for the TCM syndrome: internal blood stasis.
Study: NCT03018821
Drug: Advanced - Supplemented Taohong Huazhuo Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemented Taohong Huazhuo Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Damp-heat blocking middle jiao.
Study: NCT03018821
Drug: Standard - Chaihu Shugan San
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chaihu Shugan San is one Chinese Medicine Formula for the TCM syndrome: Liver depression and qi stagnation.
Study: NCT03018821
Drug: Advanced - Soothe the liver and regulate qi Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soothe the liver and regulate qi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Liver depression and qi stagnation.
Study: NCT03018821
Drug: Standard - Xiaoyao powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaoyao powder is one Chinese Medicine Formula for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
Study: NCT03018821
Drug: Advanced - Supplemented Ganbi Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemented Ganbi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
Study: NCT03018821
Drug: Standard - Yiguan Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiguan Decoction is one Chinese Medicine Formula for the TCM syndrome: Yin deficiency of liver and kidney.
Study: NCT03018821
Drug: Advanced - Supplemented Zimu Dan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemented Zimu Dan is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yin deficiency of liver and kidney.
Study: NCT03018821
Drug: Standard - Fuzilizhong Decoction plus Jinkui Shenqi Bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzilizhong Decoction plus Jinkui Shenqi Bolus is one Chinese Medicine Formula for the TCM syndrome: Yang deficiency of spleen and kidney.
Study: NCT03018821
Drug: Advanced - Guifu Erxian Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guifu Erxian Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yang deficiency of spleen and kidney.
Study: NCT03018821
Drug: Advanced - Supplemented Ganji Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemented Ganji Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: internal blood stasis.
Study: NCT01847274
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02837328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks